Morgan Stanley analyst Matthew Harrison ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Biogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting October 14, 2021 4:07 PM New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple SclerosisOctober 13, 2021 6:02 AM